Browse the search results

Structure and simulations reveal SARS-CoV-2 NSP10 is more resistant to genetic variations than other SARS-CoV-2 NSPs and that the presence of mutations conserves structural and dynamic changes in NSP10.

Characterisation of within-host diversity of SARS-CoV-2 provides insights into the mutational and selective mechanisms driving its evolution and has important implications for using within-host variation to inform transmission inference efforts.

Functional characterization of the alpha/B1.1.7 SARS-CoV-2 variant revealed an eightfold affinity increase of the N501Y RBD to human ACE-2 and that even a low inoculation dose of the alpha variant induces severe disease and fast progression in transgenic hACE2 mice.

A large repertoire of nanobodies that target discrete regions of SARS-CoV-2 spike shows effective neutralization against variants of concern with many pairwise combinations resistant to escape and demonstrating synergistic neutralization activities.

Flight restrictions targeted at countries where SARS-CoV-2 variant-of-concern first emerged have limited effectiveness in deterring their introduction into the Netherlands due to the strength of regional travel importation risks in Europe.

Variation in SARS-CoV-2 viral kinetics are partly explained by an individual's immune state and the infecting variant, but substantial interpersonal variation limits the reliability of isolation policies tailored to an individual's vaccination status.

Heterotypic immunity, the ability of immunity induced by one SARS-CoV-2 variant to protect against another, is asymmetric, with the UK (B.1.1.7) variant, eliciting weaker heterotypic immunity than other variants.

A replicating RNA vaccine platform generated significant immunity against SARS-CoV2 in mice and hamsters, and can be updated to target variants of concern.

Two natural tannins, oligomeric proanthocyanidins and punicalagin, acted as potent inhibitors against SARS-CoV-2 infection, and grape seed extract supplementation could serve as a healthy food for infection prevention.

Compared with casirivimab/imdevimab and bamlanivimab/etesevimab, early treatment with sotrovimab seems to reduce the time to sustained recovery among adult outpatients with mild-to-moderate SARS-CoV-2 infection due to Omicron BA.1 and BA.1.1.